Combining Acetylcysteine and Vitamin E for Mild Psoriasis Treatment

Evaluation of the Effect of Acetylcysteine and Vitamin E on Psoriasis Vulgaris Patients During The Active Phase

This study is testing if adding N-acetyl cysteine and Vitamin E to regular treatments can help people with mild psoriasis feel better.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Badr University (Academic / other)
• Drugs / interventions: Radiation
• Locations: 1 site (Cairo)
• Trial ID: NCT05906498 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of adding N-acetyl cysteine (NAC) and Vitamin E to standard treatments for patients with mild psoriasis vulgaris. A total of 60 participants will be randomly assigned to one of three groups: standard treatment alone, standard treatment plus NAC, or standard treatment plus NAC and Vitamin E. The primary outcome will be measured using the Psoriasis Area and Severity Index (PASI) score to assess improvements in clinical outcomes, oxidative stress, and inflammation over an 8-week period.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 65 with mild psoriasis in the active phase.

Not a fit: Patients with inactive psoriasis or those with serious comorbidities may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could enhance treatment outcomes for patients with mild psoriasis vulgaris.

How similar studies have performed: While the combination of NAC and Vitamin E is a novel approach, similar studies have shown promise in addressing oxidative stress in other conditions.

Eligibility criteria

Inclusion Criteria:

1. Adult Patients from 18 to 65 years.
2. Gender: both males and females.
3. Mild psoriatic patients in the active phase (score \< =3)
4. Patients diagnosed with mild psoriasis in the active phase (score less than or equal 3) using PASI score.

Exclusion Criteria:

1. Inactive psoriasis vulgaris patients.
2. Alcohol consumption
3. Any other autoimmune diseases.
4. Pregnant or lactating women.
5. Patients with serious illness and any systemic failure (cardiovascular, renal, or respiratory)
6. Patients with major psychiatric or mental illness.
7. Intake of any antioxidants in the previous 3 months
8. Patients of chronic diseases, like hypertension, heart problems
9. Patients with history of bleeding, ulcers, or uncontrollable heartburn.
10. Patients taking anticancer medications that can aggravate psoriasis vulgaris such as mercaptopurine, vinblastine, actinomycin, and Radiation

Where this trial is running

Cairo

• Al-Haud Al-Marsoud Hospital — Cairo, Egypt (Recruiting)

Study contacts

• Study coordinator: Nira Elkalla

Conditions Psoriasis Vulgaris